Anteris Technologies (ASX:AVR) one step closer to biologic heart valve
Biologic heart valve maker Anteris Technologies (AVR) is continuing to make progress…
Anteris Technologies Ltd (AVR:ASX)
$3.96
-0.08 (-1.98%)
Last trade 15.49pm 19/10/2020
20mins delayed
Latest Announcements
16/10/2020 Price SensitivePSAVRAnteris Technologies Ltd
2,468
MCap
15/10/2020AVRAnteris Technologies Ltd
1,706
MCap
09/10/2020AVRAnteris Technologies Ltd
24/09/2020AVRAnteris Technologies Ltd
636
MCap
21/09/2020AVRAnteris Technologies Ltd
1,826
MCap
08/09/2020 Price SensitivePSAVRAnteris Technologies Ltd
7,462
MCap
31/08/2020AVRAnteris Technologies Ltd
1,937
MCap
28/08/2020AVRAnteris Technologies Ltd
23,096
MCap
Company Overview
Anteris Technologies Ltd, formerly Admedus Ltd, is an Australia-based structural heart company. The Company provides solutions for heart valves. Its products include ADAPT and DurAVR. ADAPT its anti-calcification treatment platform technology on which its structural heart products are developed. DurAVR, built with ADAPT technology, is a durable three dimension (3D) single-piece aortic valve for the treatment of aortic stenosis. Its DurAVR Development Portfolio includes DurAVR Leaflet Repair (RP), DurAVR Transcatheter Heart Valve (THV) and DurAVR Surgical Heart Valve (SHV).
